Sirenia Capital Management LP and its managing principal Alex Silverstein filed an amended Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of approximately 9.9% of the common shares of Edesa Biotech, Inc. as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: Both reporting persons, Sirenia Capital Management LP and Alex Silverstein, each reported 3,339,767 common shares beneficially owned.
  • Warrant component: The 3,339,767 share total includes 2,038,636 common shares issuable upon exercise of warrants held by the Sirenia Funds.
  • Ownership percentage: The filing reports 9.9% of the class, calculated on a base of 13,511,531 common shares outstanding and giving effect to a 9.99% exercise blocker on the warrants.
  • Voting and dispositive power: Both reporting persons report zero sole voting or dispositive power, and 3,339,767 shares of shared voting and shared dispositive power.
  • 9.99% Blocker: According to the filing, the Reported Warrants cannot be exercised to the extent doing so would cause beneficial ownership to exceed 9.99% of outstanding common shares, meaning the full warrant position cannot currently be exercised.
  • Dividend rights disclosure: The filing identifies SILV Fund, Ltd. as having the right to receive, or the power to direct the receipt of, dividends from or proceeds from the sale of more than 5% of the outstanding common shares.

Sirenia Capital and Alex Silverstein Disclose Warrant-Inclusive Position in Edesa Biotech

According to the amended Schedule 13G filed with the SEC, Sirenia Capital Management LP, a Delaware limited partnership, and Alex Silverstein, the managing member of Sirenia Capital Management GP LLC (the general partner of Sirenia), reported a combined beneficial ownership position of 3,339,767 common shares, without par value, in Edesa Biotech, Inc. (NASDAQ:EDSA). The event triggering the filing occurred on September 30, 2026. The principal business address of both reporting persons is listed as 1674 Meridian Avenue, Suite 320, Miami Beach, FL 33139.

The filing states that the 3,339,767-share figure includes 2,038,636 common shares issuable upon full exercise of warrants held by investment funds managed by Sirenia (the "Sirenia Funds"). The share count in rows 6, 8, and 9 of the cover pages does not reflect the 9.99% Blocker; however, the 9.9% ownership percentage reported in row 11 does give effect to that blocker. As a result, the filing notes that "the actual number of Common Shares beneficially owned by such Reporting Person, after giving effect to the 9.99% Blocker, is less than the number of securities reported" in those rows.

The percentage calculation is based on 13,511,531 total common shares outstanding, which the filing describes as the sum of 3,870,500 shares offered pursuant to a prospectus filed under Rule 424(b)(5) on August 20, 2026, and 9,641,031 shares outstanding as of August 13, 2026, as reported in Edesa Biotech's Form 10-Q for the quarterly period ended June 30, 2026. The filing further discloses that SILV Fund, Ltd. has the right to receive or direct the receipt of dividends from, or proceeds from the sale of, more than 5% of the outstanding common shares.

What Was Disclosed

Sirenia Capital Management LP and Alex Silverstein filed an amended Schedule 13G disclosing a 9.9% beneficial ownership position in Edesa Biotech, Inc., covering 3,339,767 common shares including 2,038,636 shares issuable upon warrant exercise, subject to a 9.99% ownership blocker.